ArticleScience advances2026
A forward genetics platform for papillomavirus research.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The inability to perform forward genetics has been a major barrier to human papillomavirus (HPV) research. Here, we report a platform for phenotypic selection of HPV mutants. Our method relies on large "concordant" virus libraries, where each mutant virus particle encapsidates the mutant plasmid that encodes it, thereby directly linking viral genotype to phenotype. This platform can achieve a ∼2500-fold enrichment of an L1 capsid protein mutant from an excess of wild-type virus. To demonstrate that this system could select rare mutants from complex libraries, we selected and validated antibody escape mutants and showed that two neutralizing antibodies that recognize overlapping epitopes in L1 display distinct patterns of HPV recognition. This genetics approach unlocks previously inaccessible avenues of investigation into the HPV life cycle and provides a powerful engine to develop improved vaccines and novel antiviral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.